RP Cure Tracker

Trials / NCT06891443

Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

Recruiting now Phase 3 RNA / antisense

Sponsor
Laboratoires Thea
Treatment
sepofarsen; Placebo IVT
Gene
CEP290
Conditions
Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Sensation Disorders, Vision Disorder, Neurological Manifestations, Eye Diseases, Hereditary, Eye Diseases, Eye Disorders Congenital, Retinal Disease
Ages
6 Years to no upper limit
Enrollment
32 participants
Started
2025-06-04
Main results expected
2027-11
Results posted
Not yet
Record last updated
2026-10-21

What the study is testing

The purpose of this double-masked, randomized, placebo-controlled, paired-eye study is to evaluate the efficacy, safety and tolerability of Sepofarsen in subjects with Leber Congenital Amaurosis (LCA) due to the c.2991+1655A>G (p.Cys998X) mutation in the CEP290.

Where it runs

Australia (1)
Belgium (1)
Brazil (2)
Canada (2)
France (1)
Germany (3)
Netherlands (1)
Spain (1)
United Kingdom (1)
United States (5)

Open on ClinicalTrials.gov for contacts and eligibility